The biochemical and histopathological investigation of amlodipine in ethylene glycol-induced urolithiasis rat model

Renal Failure

Volumn 35, Issue 1, 2013, Pages 126-131

  Albayrak, Abdulmecit ^a   Bayir, Yasin ^b   Halici, Zekai ^a   Karakus, Emre ^a   Oral, Akgun ^c   Keles, Mevlut Sait ^c   Colak, Suat ^c   Zipak, Tevfik ^c   Dorman, Emrullah ^a   Uludag, Koray ^d   Yayla, Nuh ^b   Gulcan, Erim ^c  

^a ATATÜRK UNIVERSITY   (Turkey)

^b Faculty of Pharmacy   (Turkey)

^c ATATURK UNIVERSITY   (Turkey)

^d NONE   (Turkey)

Author keywords

Amlodipine; Ammonium chloride; Ethylene glycol; Rat; Urolithiasis

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; AMMONIUM CHLORIDE; CALCIUM; ETHYLENE GLYCOL; MAGNESIUM; PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL COMPOSITION; BODY WEIGHT; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CONTROLLED STUDY; CRYSTALLIZATION; HISTOPATHOLOGY; KIDNEY TUBULE DISORDER; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MALE; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; RAT; UROLITHIASIS;

AMLODIPINE; AMMONIUM CHLORIDE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM OXALATE; DISEASE MODELS, ANIMAL; ETHYLENE GLYCOL; KIDNEY; KIDNEY TUBULES; MALE; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; UROLITHIASIS;

EID: 84872444135     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.731999     Document Type: Article

References (25)

1. Araujo Viel T, Diogo Domingos C, da Silva Monteiro AP, Riggio LiM.A.-LandM.A.n MT, Lapa AJ, Souccar C. Evaluation of the antiurolithiatic activity of the extract of Costus spiralis Roscoe in rats. J EthnopharM.A.col. 1999;66:193-198. (Pubitemid 29307919)
2. Touhami M, Laroubi A, Elhabazi K, et al. Lemon juice has protective activity in a rat urolithiasismodel. BMC Urology. 2007;7:18.
3. Bayir Y, Halici Z, Keles MS, et al. Helichrysum plicatum DC. subsp. plicatum extract as a preventive agent in experimentally induced urolithiasis model. J EthnopharM.A.col. 2011;138:408-414.
4. Montjoy CA, RahM.A.n A, Teba L. Ethylene glycol and methanol poisonings: case series and review.WV Med J. 2010;106:17-23.
5. Lovric M, Granic P, Cubrilo-Turek M, Lalic Z, Sertic J. Ethylene glycol poisoning. Forensic Sci Int. 2007;170:213-215. (Pubitemid 47088875)
6. Wollersen H, ErdM.A.nn F, Risse M, Dettmeyer R. Oxalatecrystals in different tissues following intoxication with ethylene glycol: three case reports. Leg Med (Tokyo). 2009;11(Suppl. 1): S488-S490.
7. Curtin L, Kraner J, Wine H, Savitt D, Abuelo JG. Complete recovery after M.A.ssive ethylene glycol ingestion. Arch Intern Med. 1992;152:1311-1313.
8. White NC, Litovitz T, Benson BE, Horowitz BZ, M.A.rr-Lyon L, White MK. The impact of bittering agents on pediatric ingestions of antifreeze. Clin Pediatr. 2009;48:913-921.
9. Hatchett R. A severe and fatal case of ethylene glycol poisoning. Intensive Crit Care Nurs. 1993;9:183-190.
10. Domingos F, Serra A. Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. Nephrol Dial Transplant. 2011;26:864-868.
11. Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs. 2006;8:357-373. (Pubitemid 44912720)
12. Carter AJ, Gardiner DG, Burges RA. Natriuretic activity of amlodipine, diltiazem, and nitrendipine in saline-loaded anesthetized dogs. J Cardiovasc PharM.A.col. 1988;12(Suppl. 7): S34-S38. (Pubitemid 19014183)
13. Sarica K, Inal Y, Erturhan S, Yagci F. The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. Urol Res. 2006;34:184-189.
14. Toblli JE, Ferder L, Angerosa M, Inserra F. Effects of amlodipine on tubulointerstitial lesions in normotensive hyperoxaluric rats. Hypertension. 1999;34:854-858. (Pubitemid 29501312)
15. Obligado SH, Goldfarb DS. The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens. 2008;21:257-264. (Pubitemid 351323276)
16. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223. (Pubitemid 40138015)
17. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. (Pubitemid 37553153)
18. Sarica K, Erturhan S, Altay B. Effect of verapamil on urinary stone-forming risk factors. Urol Res. 2007;35:23-27.
19. Beach M.A., M.A.uro LS. PharM.A.cologic expulsive treatment of ureteral calculi. Ann PharM.A.cother. 2006;40:1361-1368. (Pubitemid 44204967)
20. Borissova A, Goltz GE, Kavanagh JP, Wilkins TA. Reverse engineering the kidney: modelling calcium oxalate monohydrate crystallization in the nephron. Med Biol Eng Comput. 2010;48:649-659.
21. Hussain M, Rizvi SA, Askari H, et al. M.A.nagement of stone disease: 17 years experience of a stone clinic in a developing country. J Pak Med Assoc. 2009;59:843-846.
22. Johns EJ. A study of the renal actions of amlodipine in the normotensive and spontaneously hypertensive rat. Br J PharM.A.col. 1988;94:311-318.
23. Sorensen MD, Duh QY, Grogan RH, Tran TC, Stoller ML. Urinary parameters as predictors of priM.A.ry hyperparathyroidism in patients with nephrolithiasis. J Urol. 2012;187:516-521.
24. Khan SR, Glenton PA. Experimental induction of calcium oxalate nephrolithiasis in mice. J Urol. 2010;184:1189-1196.
25. Spasov AA, Iezhitsa IN, Kharitonova MV, Kravchenko MS. Effects of M.A.gnesium salts on the course of experimental calcium-oxalate urolithiasis. Urologiia. 2011;2:23-29.